Immuneering Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMRX research report →
About the company
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors.
- CEO
- Benjamin J. Zeskind
- IPO
- 2021
- Employees
- 54
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $188.41M
- P/E
- -4.44
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -65.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.11%
- ROIC
- -0.03%
- Revenue
- $0 · 0.00%
- Net Income
- $-56,024,898 · 8.21%
- EPS
- $-1.27 · 37.75%
- Op Income
- $-59,375,969
- FCF YoY
- 17.42%
- 52W High
- $10.08
- 52W Low
- $2.90
- 50D MA
- $4.93
- 200D MA
- $5.69
- Beta
- 0.38
- Avg Volume
- 1.51M
Get TickerSpark's AI analysis on IMRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 23, 26 | Zeskind Benjamin J. | buy | 2,400 |
| Jun 15, 26 | Hall Brett Matthew | buy | 6,035 |
| Jun 11, 26 | Schall Thomas J. | other | 33,350 |
| Jun 11, 26 | HAUSMAN DIANA | other | 33,350 |
| Jun 11, 26 | CARPENTER ROBERT J | other | 33,350 |
| Jun 11, 26 | KEATING LAURIE | other | 33,350 |
| Jun 11, 26 | Feinberg Peter | other | 33,350 |
| Mar 13, 26 | Neufeld Leah R | other | 3,628 |
| Feb 3, 26 | Bookman Michael | other | 176,000 |
| Feb 3, 26 | Brakewood Harold Eugene | other | 140,000 |
Our IMRX coverage
Recent articles, reports, and earnings notes.
No research on IMRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMRX report →Similar companies
Peers in the same neighborhood.